Comparative Pharmacology
Head-to-head clinical analysis: DAPZURA RT versus INVOKAMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAPZURA RT versus INVOKAMET.
DAPZURA RT vs INVOKAMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective estrogen receptor degrader (SERD) and antagonist; binds to estrogen receptor alpha (ERα), induces its degradation, and inhibits estrogen-dependent growth.
INVOKAMET is a combination of canagliflozin, an SGLT2 inhibitor, and metformin, a biguanide. Canagliflozin inhibits sodium-glucose cotransporter 2 in the renal proximal tubules, reducing glucose reabsorption and increasing urinary glucose excretion. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity.
20 mg orally once daily
Oral: Starting dose: 5 mg canagliflozin/500 mg metformin hydrochloride extended-release twice daily; titrate based on efficacy and tolerability, maximum 150 mg/1000 mg twice daily.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (sufficient for once-daily dosing in most patients; prolonged in renal impairment).
Canagliflozin: 10–13 hours (multiple dosing); Metformin: 6.2 hours (plasma). Accumulation occurs in renal impairment.
Primarily renal: 70-80% unchanged in urine; biliary/fecal excretion accounts for 10-15% as metabolites.
Canagliflozin (SGLT2 inhibitor): ~33% renal (1% unchanged, ~33% as glucuronide metabolites), ~52% fecal. Metformin (biguanide): 90% renal unchanged via tubular secretion.
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor / Biguanide Combination